Gilead to buy back up to $5 bln in stock – Reuters
By Dr. Matthew Watson
RTT News | Gilead to buy back up to $5 bln in stock Reuters LOS ANGELES, May 11 (Reuters) - Biotechnology company Gilead Sciences Inc (GILD.O), whose share price has stagnated this year following ... Large buyback program from Gilead Sciences bolsters biotech sharesMarketWatch Gilead Sciences board approves $5 billion buybackBusinessWeek Gilead Preps $5B Share BuybackEmii.com |
Share
Comments are closed.
Personalized Gene Medicine
| Mesenchymal Stem Cells
| Stem Cell Treatment for Multiple Sclerosis
| Stem Cell Treatments
| Board Certified Stem Cell Doctors
| Stem Cell Medicine
| Personalized Stem Cells Therapy
| Stem Cell Therapy TV
| Individual Stem Cell Therapy
| Stem Cell Therapy Updates
| MD Supervised Stem Cell Therapy
| IPS Stem Cell Org
| IPS Stem Cell Net
| Genetic Medicine
| Gene Medicine
| Longevity Medicine
| Immortality Medicine
| Nano Medicine
| Gene Therapy MD
| Individual Gene Therapy
| Affordable Stem Cell Therapy
| Affordable Stem Cells
| Stem Cells Research
| Stem Cell Breaking Research